About Us

A scientific milestone

THE ORIGIN
OF RETICARE

September 9, 2013

Hotel Ritz · Madrid

Public launch of reticare® · Hotel Ritz, Madrid · September 2013

In 2013, researchers from the Complutense University of Madrid, led by Dr. Celia Sánchez-Ramos, presented alongside Nilo García Manchado, CEO and founder of reticare®, the results of experimental in vitro studies that demonstrated an unprecedented finding in the field of visual health.

The photoreceptor cells of the human retina suffer massive and irreversible damage when exposed to high-energy LED light — the same light emitted by every digital screen we use every day.

The most alarming part: that damage doesn't hurt. It doesn't warn you. It accumulates silently over years, unperceived by the person affected, until the consequences are irreversible.

The event brought together researchers, ophthalmologists, and media. It was the first public warning about a risk that, at the time, few wanted to acknowledge — and that today affects millions of people around the world.

"Human retinal cells suffer massive cell death when directly exposed to high-energy LED light."

Dr. Celia Sánchez-Ramos · Complutense University of Madrid · 2013

This is where the reticare® mission begins.

See the scientific evidence →

From pioneers to world reference

Over 20 years
building the evidence

2002 The beginning of the research

First experimental studies on the retina

Dr. Celia Sánchez-Ramos begins the first studies at UCM on the impact of high-energy light on retinal photoreceptor cells. Animal models with rats. The starting point for everything.

2009 International recognition

WIPO Award — Best International Female Inventor

The World Intellectual Property Organization recognizes Dr. Sánchez-Ramos' work with the Best International Female Inventor award, validating the global significance of the research.

2010 UN recognition

Grand Prize for Best International Invention

The United Nations awards the Grand Prize for Best International Invention to the technology developed at UCM. Research on retinal protection against LED light is recognized as one of the most relevant breakthroughs of the year.

2012 Academic recognition

Nomination for the Prince of Asturias Award

Dr. Sánchez-Ramos' research is nominated for the Prince of Asturias Award for Scientific and Technical Research, cementing her position as a world authority on digital light phototoxicity.

2013 The birth of reticare®

Public launch — Hotel Ritz, Madrid

On September 9th, Dr. Sánchez-Ramos and Nilo García Manchado present experimental evidence to researchers, ophthalmologists, and media: high-energy LED light irreversibly destroys retinal photoreceptor cells. The reticare® mission is born.

2015 North American expansion

Incorporation of Reticare Inc. in the United States

reticare® establishes its US subsidiary, Reticare Inc., consolidating its presence in the North American market. The UCM-developed technology for retinal protection against high-energy light (380–590 nm) becomes accessible in one of the world's largest digital markets.

2017 International scientific validation

Results presented at Harvard and the Madrid College of Physicians

Experimental findings from animal model studies are presented at Harvard University and before the Official College of Physicians of Madrid. The scientific evidence on retinal damage from high-energy LED exposure reaches the world's most demanding academic forums.

2021 Technology legal protection

Patents granted in the US and Europe

reticare® obtains formal patent grants in both the United States and Europe, consolidating the legal protection of the UCM-developed technology. An institutional validation confirming the originality and scientific value of the preventive solution against retinal damage from high-energy light.

Today Global presence

600,000+ users protected across 30+ countries

reticare® is today the only preventive solution against screen-induced retinal damage with an international patent backed by real scientific evidence. Over 12 years of history and a presence in more than 30 countries. reticare® also advises governments and institutions on the serious risks of failing to adopt scientifically validated eye protection measures for citizens and workers exposed to screens. One mission: ensuring digital progress doesn't come at the cost of people's visual health.

The track record in numbers

Data that backs a scientific legacy

+600K

Users protected worldwide

reticare® technology present in over 30 countries across five continents.

+20

Years of pioneering scientific research

From the first UCM studies to in vivo and in vitro validation of the technology.

+1,500

Participants in experimental studies

Research with animal and human models backing the preventive efficacy of reticare® products.

+30

Countries with active reticare® presence

From Spain to the United States, across Europe, Latin America, and Asia. A global mission.

What defines us

Three principles that haven't
changed in 20 years

Scientific responsibility

reticare® is built on evidence and accepts the responsibility to act when that evidence reveals a real risk to visual health. Every product, every message, and every decision is grounded in knowledge validated in vivo and in vitro by the Complutense University of Madrid. Not trends. Not opinions. Science.

+20 years of real
scientific research

Long-term commitment

From the first experimental study in 2002 to today, reticare® maintains a constant, uninterrupted commitment to eye protection. We're not a trend product or a digital health startup. We are the direct result of over two decades of rigorous, sustained work oriented toward a single goal: reducing the real impact of daily screen exposure.

2002 start of the first
UCM studies

Pioneers, not a trend

When reticare® first warned about retinal damage from LED light, nobody was talking about blue light. That was 2013. Today that message is mainstream — and there are hundreds of products using it as a marketing hook with zero real scientific backing. We've been saying it for over 12 years, and we remain the only solution with an international patent validated by UCM.

+12 years ahead
of everyone else

CEO and Founder of reticare®

Nilo García

Nilo García Manchado brought the strategic and technological perspective that made it possible to turn a university scientific patent into a real market solution. With an extensive background in the Information Technology sector, he understood before anyone else that the increasing brightness and resolution of new screens would carry a biological cost the industry was choosing to ignore.

As CEO and founder, he has led reticare®'s international expansion — now present in over 30 countries — without losing sight of the original mission: ensuring that digital progress doesn't compromise the visual health of future generations. His ultimate goal is to establish new safety standards in the technology industry.

Scientific Director and Inventor

Dr. Celia
Sánchez-Ramos

Dr. Celia Sánchez-Ramos is the world's foremost authority on digital light phototoxicity. Holding a doctorate from the Complutense University of Madrid in Preventive Medicine and Vision Sciences, she has spent over 20 years leading the pioneering studies that proved exposure to high-energy LED light (380–500 nm) causes irreversible cell death in the human retina.

Her commitment goes beyond the laboratory. She co-founded reticare® to turn her scientific findings into an accessible preventive solution. Under her scientific direction, reticare® is not an accessory — it is the direct application of over two decades of university research in service of people's visual health.